NewsRoom Articles - Page 44 of 1387

ThursdayJul 10, 2025 9:00 am

New ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) CEO Discusses Background, Outlines Direct Revenue Building Strategy, Offers Forecast for Gold Market

Vancouver-based ESGold recently announced a leadership transition, as new CEO Gordon Robb comes aboard and former CEO Paul Mastantuono moves into COO position The new CEO talked about how the company’s near-term cash flow strategy, moving right to production from processing historic tailings, funding future exploration, is a more attractive opportunity to a risk-off investor market ESGold expects to begin mill circuit production on a tailings cleanup project later this year at an abandoned mine in Quebec The company holds 265 mining claims on the historic Montauban mine site and expects the tailings cleanup to both improve the environment and…

WednesdayJul 09, 2025 9:45 am

ONAR Holding Corp. (ONAR): In Marketing’s AI Era, Strategy is Beating Speed

ONAR's network of technology-first agencies focuses on data-driven strategy and execution over flashy, reactive campaigns The company's proprietary AI platform Cortex drives results across integrated performance media, SEO, and industry-specialized marketing Recent industry studies show that sustainable growth in marketing is increasingly tied to strategic consistency and AI integration For years, speed was king in digital marketing. Agencies raced to deploy campaigns, iterate quickly, and exploit trends before they faded. But in 2025, this "move fast and break things" mindset is showing its limits. The rise of AI and the complexity of today’s customer journeys require more than just agility;…

WednesdayJul 09, 2025 9:00 am

Safe Pro Group Inc. (NASDAQ: SPAI) Is ‘One to Watch’

Unique, battle-tested and patented AI image analysis technology ready for commercialization in U.S. defense and public safety markets following more than two years of real-world usage in Ukraine. Well positioned to capitalize on U.S. military’s increased strategic focus on domestically produced drone and AI technologies through integration with currently deployed platforms such as the U.S. Army’s Tactical Assault Kit (“TAK”) ecosystem for military force protection. The patented SpotlightAI(TM) platform enables real-time detection of over 150 types of mines and UXO using AI and drone imagery and is now operating at scale, creating the world’s largest datasets of real-world landmines and…

WednesdayJul 09, 2025 9:00 am

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NetworkNewsWire Editorial Coverage: Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades. By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is taking a bold approach to this challenge with a next-generation platform designed to…

TuesdayJul 08, 2025 9:45 am

Safe Pro Group Inc. (NASDAQ: SPAI) Joins Russell Microcap(R) Index, Signaling Growing Investor Recognition, Market Visibility

Safe Pro leverages patented AI and drone-based imagery analysis for threat detection and demining efforts. Membership in the index reflects the company’s growing market presence and performance in AI-powered security and defense solutions, boosting visibility among institutional investors and fund managers. The company’s flagship SpotlightAI(TM) platform has analyzed over 1.6 million real-world battlefield images from Ukraine, identifying more than 28,000 explosive threats. Safe Pro is targeting a share of the global $15 billion defense technology market through its U.S.-made and HUBZone-certified offerings. Safe Pro Group (NASDAQ: SPAI), an emerging provider of AI-powered security and threat detection solutions, announced its addition…

TuesdayJul 08, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA. Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression. HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49%…

MondayJul 07, 2025 12:30 pm

New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Positioned to Supply Critical Global Silver Demand from Bolivia Assets

New Pacific Metals owns two of the largest undeveloped open-pit silver projects globally, both located in Bolivia. Its flagship Silver Sand project is projected to produce 12 million ounces of silver annually at low all-in sustaining costs. The Carangas project could add 6.6 million ounces of silver annually, with over 1 million ounces of gold potential at depth. New Pacific is working through Bolivia’s permitting process to unlock the upside potential of its high-quality, large-scale projects. Global silver demand, particularly for industrial and renewable energy applications, adds urgency to project development. New Pacific Metals (NYSE American: NEWP) (TSX: NUAG), a…

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving…

MondayJul 07, 2025 11:05 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Drives Metallurgical Testing to Unlock Santa Fe Value

Lahontan has commenced column leach testing at Santa Fe, targeting more efficient cyanide leach gold recovery in the mixed oxide-sulfide transition zone The Santa Fe project serves as the backbone of Lahontan's development strategy Beyond metallurgical testing, Lahontan is preparing for an expanded 2025 drilling campaign to resource growth and project optimization Lahontan (TSX.V: LG) (OTCQB: LGCXF) is accelerating its mission to develop top-tier gold and silver assets in Nevada’s renowned Walker Lane, with a renewed focus on advancing the Santa Fe project toward production. In its latest strategic move to accomplish that mission, the company has initiated in-depth metallurgical…

MondayJul 07, 2025 9:00 am

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

NetworkNewsWire Editorial Coverage: An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both…

Financial news and publishing for public and private companies

Contact us: 512.354.7000